Blosozumab|cas:1132758-87-2|西域试剂

Blosozumab,98.20%

产品编号：Bellancom-P99186| CAS NO：1132758-87-2

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99186	￥3500.00	杭州北京（现货）
Bellancom-P99186	￥9000.00	杭州北京（现货）
Bellancom-P99186	￥13500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Blosozumab

产品介绍

Blosozumab (LY2541546) 是一种抗人 sclerostin (SOST) 的抗体抑制剂。Blosozumab 可刺激骨形成并减少骨吸收。Blosozumab 可用于骨质疏松症的研究。

生物活性

Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis.

体外研究

体内研究

Blosozumab (1-100 mg/kg, i.v.) shows effects of hyperostosis in rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley rats
Dosage:	1, 10, and 100 mg/kg
Administration:	Intravenous injection (i.v.), once every 3 days (5-week study) or once weekly (6-month study)
Result:	Observed the bone anabolic effects. Showed significant bleeding and morbidity at 100 mg/kg. Decreases in the numbers of platelets. Increased number of bone marrow megakaryocytes at 100 mg/kg.

体内研究

Blosozumab (1-100 mg/kg, i.v.) shows effects of hyperostosis in rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley rats
Dosage:	1, 10, and 100 mg/kg
Administration:	Intravenous injection (i.v.), once every 3 days (5-week study) or once weekly (6-month study)
Result:	Observed the bone anabolic effects. Showed significant bleeding and morbidity at 100 mg/kg. Decreases in the numbers of platelets. Increased number of bone marrow megakaryocytes at 100 mg/kg.